{"id":822568,"date":"2025-03-06T08:55:34","date_gmt":"2025-03-06T13:55:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/"},"modified":"2025-03-06T08:55:34","modified_gmt":"2025-03-06T13:55:34","slug":"moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/","title":{"rendered":"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims<\/i>\n      <\/p>\n<p class=\"prntac\">\n        <i>Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second half of 2025<\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">HOUSTON<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 6, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<b><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376812-1&amp;h=3904196879&amp;u=https%3A%2F%2Fwww.moleculin.com%2F&amp;a=Moleculin+Biotech%2C+Inc.\" target=\"_blank\" rel=\"nofollow\">Moleculin Biotech, Inc.<\/a><\/b>, (Nasdaq: MBRX) (Moleculin or the Company),\u00a0a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, &#8220;<i>Method of Reconstituting Liposomal Annamycin<\/i>&#8220;. The grant is subject to payment of fees and completion of final amendments and formalities. Such grant will enhance the global exclusivity of Annamycin with the potential to be a next generation, non-cardiotoxic treatment for certain cancers.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg\" title=\"(PRNewsfoto\/Moleculin Biotech, Inc.) (PRNewsfoto\/Moleculin Biotech, Inc.)\" alt=\"(PRNewsfoto\/Moleculin Biotech, Inc.) (PRNewsfoto\/Moleculin Biotech, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>When issued, the patent claims will cover methods of making liposomal Annamycin suspension as well as the resulting compositions for use in the treatment of cancers, with a base patent term currently extending until <span class=\"xn-chron\">June 2040<\/span>, subject to extension to account for time required to fulfill requirements for regulatory approval. Moleculin&#8217;s novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets). Additional preclinical studies performed at a world-renowned cancer center indicate Annamycin may be a potential treatment for many more other types of cancers. The new chemical entity uses a unique lipid-based delivery technology and has shown the potential to be used in a wide range of cancers. In addition to the expected European patent and previously issued U.S. patents, Moleculin has additional patent applications related to Annamycin pending in the U.S., <span class=\"xn-location\">Europe<\/span> and in major jurisdictions worldwide.\u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Wally Klemp<\/span>, Chairman and CEO of Moleculin, said &#8220;Acknowledgment by the European Patent Office of the innovation underlying Annamycin is an important milestone for Moleculin, underscoring the importance and proprietary nature of the innovation that makes this next generation anthracycline possible.\u00a0 We expect <span class=\"xn-location\">Europe<\/span> to be an important market for Annamycin and look forward to making an important new treatment available to patients in this region. This enhancing of our exclusivity for Annamycin is exciting when coupled with our continued expectation for an initial data readout for the MIRACLE trial in the second half of 2025.&#8221;<\/p>\n<p>The Company is initiating the MIRACLE (<b>M<\/b>olecul<b>i<\/b>n <b>R<\/b>\/R AML <b>A<\/b>nnAraC <b>Cl<\/b>inical <b>E<\/b>valuation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase <span class=\"xn-money\">1B<\/span>\/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.<\/p>\n<p>Additionally, the Company is developing WP1066, an Immune\/Transcription Modulator capable of inhibiting p-STAT3 and other\u00a0oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.<\/p>\n<p>For more information about the Company, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376812-1&amp;h=60414863&amp;u=http%3A%2F%2Fwww.moleculin.com%2F&amp;a=www.moleculin.com\" target=\"_blank\" rel=\"nofollow\">www.moleculin.com<\/a> and connect on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376812-1&amp;h=4173901625&amp;u=https%3A%2F%2Fwww.twitter.com%2Fmoleculinbio&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>, <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376812-1&amp;h=888316706&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmoleculin-llc%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a> and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376812-1&amp;h=1555083571&amp;u=https%3A%2F%2Fwww.facebook.com%2Fmoleculin&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements<br \/><\/b>\n      <\/p>\n<p>Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the achievements of each of the milestones in this press release. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company&#8217;s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including &#8216;believes,&#8217; &#8216;estimates,&#8217; &#8216;anticipates,&#8217; &#8216;expects,&#8217; &#8216;plans,&#8217; &#8216;projects,&#8217; &#8216;intends,&#8217; &#8216;potential,&#8217; &#8216;may,&#8217; &#8216;could,&#8217; &#8216;might,&#8217; &#8216;will,&#8217; &#8216;should,&#8217; &#8216;approximately&#8217; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. &#8220;Risk Factors&#8221; in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>JTC Team, LLC<br \/><span class=\"xn-person\">Jenene Thomas<\/span><br \/>(908) 824-0775<br \/><a href=\"mailto:MBRX@jtcir.com\" target=\"_blank\" rel=\"nofollow\">MBRX@jtcir.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DA34332&amp;sd=2025-03-06\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity-302393600.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity-302393600.html<\/a><\/p>\n<p>SOURCE  Moleculin Biotech, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DA34332&amp;Transmission_Id=202503060830PR_NEWS_USPR_____DA34332&amp;DateId=20250306\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second half of 2025 HOUSTON , March 6, 2025 \/PRNewswire\/ &#8212;\u00a0Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company),\u00a0a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, &#8220;Method of Reconstituting Liposomal Annamycin&#8220;. The grant is subject to payment of fees and completion of final amendments and formalities. Such grant will enhance the global exclusivity of Annamycin with the potential to be a next &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-822568","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second half of 2025 HOUSTON , March 6, 2025 \/PRNewswire\/ &#8212;\u00a0Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company),\u00a0a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, &#8220;Method of Reconstituting Liposomal Annamycin&#8220;. The grant is subject to payment of fees and completion of final amendments and formalities. Such grant will enhance the global exclusivity of Annamycin with the potential to be a next &hellip; Continue reading &quot;Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-06T13:55:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity\",\"datePublished\":\"2025-03-06T13:55:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/\"},\"wordCount\":900,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/\",\"name\":\"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\",\"datePublished\":\"2025-03-06T13:55:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/959635\\\/Moleculin_Biotech_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/","og_locale":"en_US","og_type":"article","og_title":"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - Market Newsdesk","og_description":"PR Newswire New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second half of 2025 HOUSTON , March 6, 2025 \/PRNewswire\/ &#8212;\u00a0Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company),\u00a0a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, &#8220;Method of Reconstituting Liposomal Annamycin&#8220;. The grant is subject to payment of fees and completion of final amendments and formalities. Such grant will enhance the global exclusivity of Annamycin with the potential to be a next &hellip; Continue reading \"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-06T13:55:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity","datePublished":"2025-03-06T13:55:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/"},"wordCount":900,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/","name":"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","datePublished":"2025-03-06T13:55:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/959635\/Moleculin_Biotech_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=822568"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822568\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=822568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=822568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=822568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}